Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > BUSINESS
BUSINESS
- Zeria Licenses Acofide to Spanish Pharma in 13 Latin American Countries
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Mitsubishi Tanabe’s April-December Sales Fall 10.5% as Gilenya Feud Continues
February 5, 2020
- Collategene Generates Only 4 Million Yen in 4 Months
February 5, 2020
- Zeria, Kyowa Kirin to End Asacol Collaboration at March-End
February 5, 2020
- Kyowa Hakko Bio Staffers Hid GMP Violations, Fearing Supply Halt: Report
February 4, 2020
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
- Bayer, Nippon Kayaku to Copromote Prostate Cancer Med Nubeqa
February 4, 2020
- EU Filing Pulled for Opdivo/Yervoy Combo in Frontline NSCLC
February 4, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Towa Completes Buyout of Pensa Investments
February 4, 2020
- Daiichi Sankyo Espha to Launch Zetia AG in June
February 4, 2020
- Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
February 3, 2020
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
- Eisai's April-December Operating Profit Surges 28.4% on Lenvima, Guidance Lifted
February 3, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…